Recently, several prestigious annual rankings in China's pharmaceutical industry have been released sequentially, and Alphamab Oncology has won multiple honors due to its outstanding innovation strength and notable R&D achievements.
At the 16th China Healthcare Summit of Entrepreneurs, Scientists, and Investors (2024 CHSESI), Alphamab Oncology has been granted with "2024 Top 100 Chinese Pharmaceutical Innovative Enterprises". This ranking is jointly launched by Healthcare Executive and Clarivate Analytics, taking the four indications (the number of authorized patents, total number of patent citations, the number of clinical trials and the number of innovative drugs approved and commercialized) as the basis for evaluation. The Company has been selected for this list for six consecutive years.
At the 2024 CHSESI, Alphamab Oncology was also awarded the title of "2024 China Pharmaceutical Innovative Enterprise Bispecific Antibody Track TOP5". The award is jointly launched by Healthcare Executive and Clarivate Analytics after data-based screening and comprehensive appraisal of multiple dimensions such as the number of new drugs under development, the number of clinical pipelines, the value of licensing transactions, and the number of patents. The awarded pharmaceutical enterprises not only represent the highest level of China's cutting-edge technology tracks such as ADC and bispecific antibody, but also gained significant global recognition through blockbuster clinical data presented at international pharmaceutical academic conferences.
At the "2024 Healthy China Communication Conference" hosted by the China Health Culture Association, the China Hospital Association, and the National Health Commission of the People's Republic of China Health TV Channel (CHTV), the "China Medical and Health Brand Influence" list was officially released, and Alphamab Oncology was granted with "2024 Top 100 Brand Influence of Chinese Pharmaceutical Enterprise". The evaluation of brand influence is based on the Brand Influence Index developed by the Health Communication Index Research Institute, which collects and analyzes data across various dimensions, including the overall capabilities of pharmaceutical companies, the strength of their brand, and their communication effectiveness. The evaluation aims to encourage the pharmaceutical industry to pay more attention to the development of quality, innovation, social responsibility and other aspects, thereby enhancing the image and public credibility of the entire industry. Being included in the list highlights Alphamab Oncology's strong corporate competitiveness, and its drug and technology platform R&D efficiency advantages and innovation are widely recognized.
Alphamab Oncology has long focused on unmet clinical needs, dedicated to promoting clinical development of core products, continuously optimized technology platforms to enhance the differentiated advantages of product pipeline, and actively expanded international and domestic cooperations to accelerate value realization of innovative achievements. The Company has a fully integrated proprietary biologics platform in bispecific, protein engineering and antibody-drug conjugates (ADC), based on which, it has created an innovative drug product pipeline with significant competitiveness. Notably, Envafolimab, the world's first subcutaneously injectable PD-L1 inhibitor already in the market, made a significant breakthrough in the convenience and accessibility of cancer treatment. Several pivotal clinical trials of anti-HER2 bispecific antibody KN026 for neoadjuvant and the first-line treatment of breast cancer (BC) and the second-line treatment of gastric cancer (GC)/ gastroesophageal junction cancer (GEJ) are being conducted. The new generation of bispecific ADC drugs JSKN003, JSKN033, and JSKN016 are at the forefront of global innovation, and have established sustainable competitive advantages through domestic and international cooperations.
Looking ahead, Alphamab Oncology will continue to apply the operation strategy regarding "differentiated innovation driven by clinical demands" and remain committed to the long-term vision of "developing differentiated, clinically valuable and globally competitive new drugs". The Company will focus on the research and development of first-in-class innovative drugs, while accelerating clinical development, product commercialization, and international and domestic collaboration. With outstanding innovative achievements, we will continue to innovate the tumor treatment modality, light up the hope of patients, and contribute more wisdom and strength to the medical and health industry in China and around the world.
About Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company committed to the development, manufacturing, and commercialization of cutting-edge biotherapeutics for the treatment of cancer. On December 12, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.
Our integrated platform seamlessly combines research, development, and manufacturing capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification.
Distinguished by a globally competitive pipeline, Alphamab Oncology specializes in antibody-drug conjugation (ADC), single domain antibody, and bispecific antibodies. Notably, Envafolimab, the world's first subcutaneously injectable PD-L1 inhibitor, was approved by Chinese authorities in 2021, making a significant breakthrough in the convenience and accessibility of cancer treatment. Three assets are currently undergoing Phase III or pivotal clinical trials, and several other bispecific ADC new drug candidates are in early clinical stage. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, Arrivent, and Glenmark.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is dedicated to the development of safe, effective and affordable drugs, leveraging a global competitive edge.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
